Bendamustine

Bendamustine in the glossary for Waldenström's macroglobulinemia

An alkylating agent (chemotherapy)

Bendamustine, is a chemotherapy medication used in the treatment of chronic lymphocytic leukemia (CLL), multiple myeloma (MM), and non-Hodgkin's lymphoma (NHL).¹ It is administered intravenously. Bendamustine belongs to the alkylating-agent family of anticancer agents. Its mechanism of action involves interfering with the function of DNA and RNA. Bendamustine is authorized for use in a number of European countries.^2,3

Glossary overview

References

1.Bendamustine SmPC. Available from; https://www.medicines.org.uk/emc/product/7302/smpc#gref. Accessed November 12th, 2021.

2.Dennie TW and Kolesar JM. Bendamustine for the treatment of chronic lymphocytic leukemia and rituximab-refractory, indolent B-cell non-Hodgkin lymphoma. Clin Ther 2009: 31(2);2290-311.

3.Thiesen, J. Hospital Pharmacy Europe - Bendamustine. 2021. Available from; https://hospitalpharmacyeurope.com/news/editors-pick/bendamustine/. Accessed November 12th, 2021.

This website contains information for a broad scientific audience and may include information on products or indications that are not licensed, approved, or accessible in your country or region. Prescribing information or other medical information for products may also differ between countries or regions. Please consult the appropriate national or regional regulatory authority for specific information on a product or indication included here.